Trials / Unknown
UnknownNCT03060993
CAN BREATHE in COPD Trial
Effect of Inhaled Vaporized Cannabis on Pulmonary Function, Breathlessness and Exercise Tolerance in Symptomatic Patients With Advanced Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- McGill University · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A growing body of physiological evidence now exists to support a potential role for inhaled cannabis in the medical management of adults with chronic obstructive pulmonary disease (COPD), particularly as it may related to improving pulmonary function, alleviating the symptom of breathlessness and improving exercise endurance. The purpose of this randomized double-blind crossover trials is to evaluate the efficacy and physiological mechanism(s) of action of inhaled vaporized cannabis targeted to relief of physical activity-related breathlessness and exercise endurance in symptomatic patients with severe-to-very severe COPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabis | Patients will be administered cannabis (THC/CBD) in vaporized form. |
| DRUG | Placebo | Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2018-01-01
- Completion
- 2018-04-30
- First posted
- 2017-02-23
- Last updated
- 2017-02-23
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03060993. Inclusion in this directory is not an endorsement.